GlassScriptPhysician profile
Karthik Vedantam
NPI 1851753917
$3,319.07
in general payments reported to CMS, 2019-2025
19 companies · $767 in 2025
The $767 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $14.56 · 2023: $537 · 2024: $1,773 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Travel and Lodging: $538 · Grant: $272 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.49 |
| Travel and Lodging | $537.75 |
| Grant | $271.73 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,068.83 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $746.11 | 2023-2025 | Avvigo Guidance System, Watchman Flx |
| Shockwave Medical, INC | $265.49 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $245.77 | 2023-2024 | Corevalve Evolut R, Adapta |
| Amgen INC. | $216.71 | 2021-2025 | Repatha, Repatha |
| Heartflow, INC. | $147.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $125.63 | 2024-2025 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Abiomed | $74.40 | 2024 | Impella |
| Astellas Pharma US INC | $66.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $65.56 | 2021-2025 | Wainua |
| Cleerly, INC. | $46.54 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Abbott Laboratories | $43.13 | 2024-2025 | Ensite, Viewmate |
| Pfizer INC. | $24.91 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.26 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $22.94 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $21.00 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $15.98 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthik Vedantam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.